Cardiomyocytes Market Size & Share, by Type (Human iPSC-Derived Cardiomyocytes, Rat Cardiomyocytes); Application (Independent assays, Cardiac Disease Modeling, Cardiac safety & Toxicity); End-User (Private Research Laboratory, Academic Research Institute, Drug Manufacturers)-Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5972
  • Published Date: Apr 03, 2024
  • Report Format: PDF, PPT

Cardiomyocytes Market Size, Forecast, and Trend Highlights Over 2024-2036

Cardiomyocytes Market size is expected to reach USD 12 Billion by the end of 2036, growing at a CAGR of 10% during the forecast period, i.e., 2024 -2036. In the year 2023, the industry size of cardiomyocytes was USD 5 Billion. The market is thriving on the back of the rising incidence of cardiovascular diseases in the world. According to research an estimated 7% of men and around 4.5% of women suffer from heart-related diseases. The heart's rhythmic beating is regulated by cardiomyocytes, which are the cells that produce contractile force in an intact heart. Hence, increasing the demand for cardiomyocyte therapies in the world.

In addition to these, factors that are believed to fuel the market growth of the cardiomyocytes market include the growing geriatric population. Research shows that an estimated 771 million individuals worldwide were 65 years of age or older in 2022, making up about 10% of the world's population. This increases the demand for cardiomyocyte therapies as older people are more susceptible to cardiovascular diseases. 


Cardiomyocytes Market overview
Get more information on this report: Request Free Sample PDF

Cardiomyocytes Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Investments in Research and Development - Huge pharmaceutical and biotech companies like Acesion Pharma, Acticor Biotech, SKG International, and many more spend heavily on research, development, and commercialization of cardiomyocyte-based therapies like cardiomyocyte stimulation, progenitor differentiation, and direct lineage. The increasing investments in research and rapid development of Cardiomyocytes it is likely to spur market growth in the coming years. Furthermore, governmental funding agencies like the National Institute of Health (NIH) also invest in the research and development of cardiomyocyte-based regenerative therapies which is driving the cardiomyocytes market growth in the forecast period.
  • Expanding Adoption of Cell Therapy -  Healthcare providers' increasing acceptance and use of cell therapy techniques, such as cell-based heart regeneration and cardiomyocyte transplantation, due to its utilization of stem cell treatment and their derivatives to enhance the body's natural ability to repair damaged malfunctioning or damaged tissue, and the growing volume of clinical evidence demonstrating the safety and effectiveness of these treatments is causing them to be incorporated into standard treatment plans for specific cardiovascular diseases is also further propelling the growth of the cardiomyocyte market.
  • Increase in Healthcare Expenditure and Reimbursement Policies - One of the elements anticipated to fuel cardiomyocytes market expansion during the forecast period is the recent increase in healthcare spending driven by the strengthening economy. Therefore, the positive reimbursement policies offered by both public and private insurers raise awareness and demand for cardiomyocyte therapies. Insurance companies that pay for therapy lessen the financial strain on patients, which increases the chance that they will seek treatment and adhere to recommendations. For instance, according to the data published by the World Bank in 2020 the world spent 10.89% of its total GDP on healthcare.

Challenges

  • High Cost of Production - Producing high-quality cardiomyocytes at a high scale requires sophisticated manufacturing processes, specialized equipment, and skilled personnel. The complexity of cell culture techniques, purification methods, and quality control measures contributes to manufacturing expenses. Hence, hindering the cardiomyocytes market growth.
  • Regulatory requirements for safety efficacy and quality assurance can hamper the market growth.
  • Lack of infrastructure and equipment in developing and underdeveloped countries can also impede market growth.

Cardiomyocytes Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~10%

Base Year Market Size (2023)

~ USD 5 Billion

Forecast Year Market Size (2036)

~ USD 12 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Cardiomyocytes Segmentation

 Type (Human iPSC-Derived Cardiomyocytes, Rat Cardiomyocytes)

The human iPSC-derived cardiomyocytes segment is predicted to account for 60% share of the cardiomyocytes market by 2036. The segment growth can be attributed to the rising prevalence of cardiovascular diseases, such as coronary heart disease, stroke, hypertension, and congestive heart failure. According to the data published by the World Health Organization cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Cardiomyocytes produced from induced pluripotent stem cells (iPSC) can improve the precision, efficacy, and accuracy of identifying cardiovascular damage hazards in drugs as well as non-pharmaceutical methods. Hence, increasing the demand for human iPSC-derived cardiomyocytes in the cardiomyocytes market.

Application (Independent assays, Cardiac Disease Modeling, Cardiac safety & Toxicity)

Cardiac safety and toxicity segmented in cardiomyocytes market is estimated to gain a significant share during the forecast period. The segment growth can be attributed to the global rise in cardiotoxicity brought on by an increased prevalence of cancer. Cardiotoxicity is the term for heart damage caused by several cancer medications or treatments and results in cardiac diseases including but not limited to arrhythmia, myocardial infarction, and myocardial hypertrophy. Research by the World Cancer Research Fund Internation shows that there were an estimated 18.1 million cancer cases around the world in 2020. Thus showing significant growth in the cardiomyocyte market in the forecast period.

Our in-depth analysis of the Cardiomyocytes market includes the following segments:

          Type

  • Human iPSC-derived Cardiomyocytes
  • Rat Cardiomyocytes

          Application

  • Independent assays
  • Cardiac Disease Modeling
  • Cardiac safety & Toxicity

          End-Users

  • Private Research Laboratory
  • Academic Research Institute
  • Drug Manufacturers 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cardiomyocytes Industry - Regional Synopsis

North America Market Forecast

The cardiomyocytes market in the North American region, amongst the market in all the other regions, is anticipated to hold the largest with a share of about ~35% by the end of 2036. The market growth in the region is expected to grow on account of the presence of major key players such as Axol Bioscience Ltd, Cell Applications Inc., Cellular Dynamics International, and R&D Systems Inc. in the region. Moreover, the Boston-Cambridge biotech cluster and San Francisco Bay Area Silicon Valley in the United States serve as the epicenter of cardiomyocyte research investments and entrepreneurship. Additionally, the high prevalence of cardiovascular disease due to unhealthy lifestyles in the region is also expected to further propel the market growth. According to data published by a government website about 695,000 people in the United States died from heart disease in 2021. Increasing the demand for newer and more effective forms of treatment like cardiomyocyte therapies in the region.

APAC Market Analysis

The Asia Pacific market is estimated to be the second largest, registering a share of about ~20% by the end of 2036. The market’s expansion can be attributed majorly to the increasing demand for cardiac testing in fast-emerging countries such as India, China, Vietnam, and Indonesia, as a result of rising cardiovascular diseases in the region. According to research around 5 million people in India died due to cardiovascular diseases in 2020 and an estimated 4.58 million deaths occurred in 2020 in China due to cardiovascular disease. Furthermore, the growing aging population of this region due to increasing longevity and falling fertility is also expected to propel the market growth. For instance, in 2020 there were an estimated 140 million people aged 60 and above in India, and in 2019 an estimated 250 million people in China were aged 60 years or older. Thus, increasing the demand for cardiomyocytes in the Asia-Pacific region.

Research Nester
Cardiomyocytes Market size
Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Cardiomyocytes Landscape

top-features-companies
    • AstraZeneca
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis
    • Pfizer
    • Roche
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Bayer
    • Abbott Laboratories
    • Bristol Myres
    • Cytiva

In-the-news

In The News

  • 31st January 2024

Abbott Park, Illinois /PRNewswire/ -- The world leader in science-based nutrition, Abbott (NYSE: ABT), has announced the introduction of its new PROTALITYTM brand. The first product in this range to cater to the increasing number of adults who want to lose weight without sacrificing healthy nutrition and muscle mass is the high-protein nutrition smoothie.

  • 6th December 2023

Novartis announced that Fabhalta® (iptacopan) has been approved by the U.S. Food and Drug Administration (FDA) as the first oral monotherapy for the management of adults suffering from paroxysmal nocturnal hemoglobinuria (PNH)1. A Factor B inhibitor, fabhalta functions proximally in the immune system's alternative complement pathway, offering complete regulation of the destruction of red blood cells (RBCs) both inside and outside of blood vessels (intra- and extravascular hemolysis [IVH and EVH]).

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5972
  • Published Date: Apr 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the Cardiomyocytes market are the rising incidence of cardiovascular diseases in the world, rising investments in research and development, expanding adoption of cell therapy, and increase in healthcare expenditure and reimbursement policies.

The market size of cardiomyocytes is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024-2036.

The major players in the market are AstraZeneca, Novartis, Pfizer, Roche, Johnson & Johnson, Merck & Co., Inc., Bayer, Abbott Laboratories, Bristol Myres, Cytiva, and others.

The Human iPSC-derived Cardiomyocytes segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Cardiomyocytes Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying